Safety and Efficacy of CC-10004 for Prurigo Nodularis

Inclusion Criteria: * Must understand and voluntarily sign an informed consent form * Must be male or female and aged ≥ 18 years at time of consent * Must be able to adhere to the study visit schedule and other protocol requirements * Must have a diagnosis of prurigo nodularis based on clinical and histological findings and have failed four weeks of treatment with topical therapies, including corticosteroids and/or vitamin D derivatives. * Must meet the following laboratory criteria: * Hemoglobin WNL * Hematocrit WNL * White blood cell (WBC) count WNL * Neutrophils ≥ 1500 /dL * Platelets ≥ 100,000 /dL * Serum creatinine ≤ 1.5 mg/dL * Total bilirubin 2.0 mg/dL * Aspartate transaminase (AST \[serum glutamic oxaloacetic transaminase, SGOT\]) and alanine transaminase (ALT \[serum glutamate pyruvic transaminase, SGPT\]) 1.5x upper limit of normal (ULN) * Females of childbearing potential (FCBP) must have a negative urine pregnancy test at screening (Visit Must have a negative purified protein derivative (PPD) within 28 days of the baseline visit. * Must have a negative purified protein derivative (PPD) within 28 days of the baseline visit. Exclusion Criteria: * History of cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases deemed clinically significant by the investigator * Any systemic treatment (including ultraviolet light, corticosteroids, thalidomide, azathioprine, cyclosporine) within 28 days of study drug administration. * Any topical treatments (including corticosteroids, vitamin D derivatives) within 14 days of study drug initiation. * Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. * Pregnant or lactating female.